Home / Risankizumab / Czechia
CZ ATC L04AC18 · updated 2 Nov 2026
Risankizumab shortage in Czechia
Is there a Risankizumab shortage in Czechia?
Yes. As of 2 Nov 2026, 1 Risankizumab product is reported short in Czechia, the first since 31 Jan 2024. The company estimate for the return is 31 Jan 2028. Main reason: commercial decision or withdrawal.
Not reported short in any other country we track. All countries.
Affected products in Czechia
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CZ | SKYRIZI 150MG 150MG INJ SOL PEP 1X1ML | AbbVie Deutschland GmbH & Co.KG, Ludwigshafen | 31 Jan 2024 | 31 Jan 2028 | Commercial decision or withdrawal Obchodní/marketingové důvody |
Source
SÚKL (State Institute for Drug Control), market reports. Official list. Products whose latest market report is a supply interruption; one row per SÚKL code.